Intuitive Surgical Beats Q4 Estimates: Trending Tickers
Generated by AI AgentMarcus Lee
Wednesday, Jan 15, 2025 4:05 pm ET2min read
ISRG--
Intuitive Surgical (ISRG), the global leader in robotic-assisted surgery, reported strong preliminary Q4 and full year 2024 results, beating analysts' estimates. The company's da Vinci surgical systems continue to drive growth, with a 18% increase in worldwide procedures in Q4 2024 compared to Q4 2023. For the full year, da Vinci procedures grew by 17% compared to 2023, with the company expecting worldwideda Vinciprocedures to increase approximately 13% to 16% in 2025.
Intuitive Surgical's revenue also saw significant growth, with preliminary Q4 2024 revenue increasing by 25% to approximately $2.41 billion, driven by growth in da Vinci and Ion procedure volume and customer buying patterns. Full-year 2024 revenue grew by 17% to approximately $8.35 billion, primarily driven by growth in da Vinci and Ion procedure volume.
The company placed 493 da Vinci surgical systems in Q4 2024, a 19% increase compared to Q4 2023, with 174 of those being da Vinci 5 systems. During 2024, Intuitive Surgical placed 1,526 da Vinci surgical systems, a 11% increase compared to 2023, with 362 of those being da Vinci 5 systems.
Intuitive Surgical's strong performance can be attributed to several factors, including the growing demand for minimally invasive surgery, improving reimbursement policies, and technological advancements in da Vinci systems. The company's extensive global presence and market penetration have also contributed to the growth in da Vinci system placements and procedures.
Despite the strong performance, Intuitive Surgical's share price dropped by 8% during pre-market trading after announcing Q3 earnings. This decline may be due to increased competition from companies such as CMR Surgical, which recently received $165 million in funding for its product Versius, and the Australia-based company Interventional Systems, which received FDA approval for the use of the Micromate in the US.
Intuitive Surgical's growth strategy has evolved over the past year, focusing on expanding its product portfolio and entering new markets. In 2023, the company launched the da Vinci Xi and X systems, which are designed to be more compact and affordable than previous models. Additionally, Intuitive has been expanding its presence in international markets, particularly in Asia and Europe. The company has also been investing in research and development to create new products and technologies, such as the Ion endoluminal system, which is designed to treat lung cancer. Furthermore, Intuitive has been exploring partnerships and collaborations with other companies to expand its reach and enhance its offerings.
In conclusion, Intuitive Surgical's strong Q4 and full year 2024 results demonstrate the company's continued dominance in the robotic-assisted surgery market. Despite increased competition, Intuitive Surgical's growth strategy, technological advancements, and global presence position the company well for future success. As the demand for minimally invasive surgery continues to grow, Intuitive Surgical is well-positioned to capitalize on this trend and maintain its market leadership.
Intuitive Surgical (ISRG), the global leader in robotic-assisted surgery, reported strong preliminary Q4 and full year 2024 results, beating analysts' estimates. The company's da Vinci surgical systems continue to drive growth, with a 18% increase in worldwide procedures in Q4 2024 compared to Q4 2023. For the full year, da Vinci procedures grew by 17% compared to 2023, with the company expecting worldwideda Vinciprocedures to increase approximately 13% to 16% in 2025.
Intuitive Surgical's revenue also saw significant growth, with preliminary Q4 2024 revenue increasing by 25% to approximately $2.41 billion, driven by growth in da Vinci and Ion procedure volume and customer buying patterns. Full-year 2024 revenue grew by 17% to approximately $8.35 billion, primarily driven by growth in da Vinci and Ion procedure volume.
The company placed 493 da Vinci surgical systems in Q4 2024, a 19% increase compared to Q4 2023, with 174 of those being da Vinci 5 systems. During 2024, Intuitive Surgical placed 1,526 da Vinci surgical systems, a 11% increase compared to 2023, with 362 of those being da Vinci 5 systems.
Intuitive Surgical's strong performance can be attributed to several factors, including the growing demand for minimally invasive surgery, improving reimbursement policies, and technological advancements in da Vinci systems. The company's extensive global presence and market penetration have also contributed to the growth in da Vinci system placements and procedures.
Despite the strong performance, Intuitive Surgical's share price dropped by 8% during pre-market trading after announcing Q3 earnings. This decline may be due to increased competition from companies such as CMR Surgical, which recently received $165 million in funding for its product Versius, and the Australia-based company Interventional Systems, which received FDA approval for the use of the Micromate in the US.
Intuitive Surgical's growth strategy has evolved over the past year, focusing on expanding its product portfolio and entering new markets. In 2023, the company launched the da Vinci Xi and X systems, which are designed to be more compact and affordable than previous models. Additionally, Intuitive has been expanding its presence in international markets, particularly in Asia and Europe. The company has also been investing in research and development to create new products and technologies, such as the Ion endoluminal system, which is designed to treat lung cancer. Furthermore, Intuitive has been exploring partnerships and collaborations with other companies to expand its reach and enhance its offerings.
In conclusion, Intuitive Surgical's strong Q4 and full year 2024 results demonstrate the company's continued dominance in the robotic-assisted surgery market. Despite increased competition, Intuitive Surgical's growth strategy, technological advancements, and global presence position the company well for future success. As the demand for minimally invasive surgery continues to grow, Intuitive Surgical is well-positioned to capitalize on this trend and maintain its market leadership.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet